Clinical evidence demonstrates that PD‐1 pathway blockade effectively inhibits IFNγ signaling in breast cancer, melanoma, and CRC cells, thereby alleviating T cell exhaustion and enhancing CD8+ T lymphocyte‐mediated antitumor immunity [598]. Here, IFNG is linked to melanoma.